Pain Therapeutics, King start phase 1 trial for Oradur-based pain reliever

By Elaine Rigoli

Tampa, Fla., Aug. 2 - Pain Therapeutics Inc. and King Pharmaceuticals Inc. said they have started a phase 1 clinical trial to evaluate the effects of opioid painkiller PTI-202 in humans.

Pain Therapeutics recently submitted an Investigational New Drug application to the Food and Drug Administration for PTI-202.

FDA acceptance triggered the payment of a $5 million cash milestone from King to Pain Therapeutics, according to a news release.

In November 2005, Pain Therapeutics and King announced an alliance to develop and commercialize four proprietary lead drug candidates. All four drug candidates are intended to be long-acting, abuse-resistant opioid painkillers.

The products under this collaboration are formulated with Durect Corp.'s Oradur technology under a development and license agreement between Durect and Pain Therapeutics.

The first drug candidate under development by Pain Therapeutics and King Pharmaceuticals, Remoxy (Oradur-based oxycodone), is in phase 3 clinical testing.

Pain Therapeutics is a biopharmaceutical company located in South San Francisco, Calif.

King, based in Bristol, Tenn., is a branded pharmaceutical company.

Durect is an emerging specialty pharmaceutical company based in Cupertino, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.